文献速递头颈PETCT

18F-氟脱氧葡萄糖正电子发射断层显像/计算机体层成像联合血小板-淋巴细胞比率预测鼻咽癌预后的价值

Usefulness of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography combined with the platelet-lymphocyte ratio in predicting the prognosis of nasopharyngeal carcinoma.
PubMed 文献 · Br J Radiol · 2021-11-23

回顾性分析73例治疗前接受18F-FDG PET/CT的鼻咽癌患者,测量原发灶SUVmax与治疗前1周内PLR。SUVmax=9.7、PLR=132.98为最佳预后诊断界值,二者均为无进展生存的独立影响因素,联合应用可更准确预测预后。

要点

  • 鼻咽癌原发灶SUVmax=9.7、PLR=132.98为最佳预后界值。
  • 高PLR组中SUVmax<9.7者5年PFS 59.3% vs ≥9.7者29.4%(p=0.033)。
  • 低PLR组中SUVmax<9.7者5年PFS 90.9% vs ≥9.7者42.9%(p=0.006)。

核心结论

  • 原发灶SUVmax与治疗前PLR均对鼻咽癌预后有重要影响,二者联合可更准确预测患者预后。
  • SUVmax与PLR均为鼻咽癌无进展生存的独立影响因素,低SUVmax(<9.7)联合低PLR(<132.98)显示显著的PFS获益。

研究设计与样本

  • 回顾性分析2010年1月至2014年12月治疗前接受18F-FDG PET/CT的73例鼻咽癌患者数据。
  • 测量鼻咽癌原发灶SUVmax及治疗前1周内PLR,以ROC曲线获取最佳界值并据此分组。
  • 采用Kaplan-Meier法与Log-rank检验进行5年PFS单因素分析,Cox回归进行多因素分析。

关键影像表现/征象

  • 5年内疾病进展患者的SUVmax与PLR均高于无进展患者(p=0.006与p=0.026)。
  • 高PLR组(PLR≥132.98)中SUVmax<9.7者5年PFS 59.3% vs SUVmax≥9.7者29.4%(p=0.033)。
  • 低PLR组(PLR<132.98)中SUVmax<9.7者5年PFS 90.9% vs SUVmax≥9.7者42.9%(p=0.006)。
  • SUVmax<9.7患者中,高PLR组5年PFS 59.3% vs 低PLR组90.9%(p=0.016)。
  • SUVmax≥9.7患者中,高PLR组与低PLR组5年PFS 29.4% vs 42.9%,无显著差异(p=0.406)。

诊断标准与关键数值

  • SUVmax最佳预后诊断界值为9.7,PLR最佳预后诊断界值为132.98。
  • 按PLR≥132.98为高PLR组、PLR<132.98为低PLR组,按SUVmax≥9.7与<9.7分组。
  • Cox多因素分析显示SUVmax与PLR为影响鼻咽癌预后的独立因素。

临床应用与阅片要点

  • 治疗前18F-FDG PET/CT测量原发灶SUVmax并结合治疗前1周内PLR,可对鼻咽癌患者进行预后分层。
  • 低SUVmax(<9.7)联合低PLR(<132.98)提示显著的PFS获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the value of 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/computed tomography (CT) combined with the platelet-lymphocyte ratio (PLR) in predicting the prognosis of nasopharyngeal carcinoma (NPC).

METHODS: This was a retrospective analysis of the data of 73 patients with NPC who underwent 18F-FDG PET/CT before treatment from January 2010 to December 2014. The maximum standard uptake value (SUVmax) of NPC and the PLR within 1 week before treatment were both measured. The Mann-Whitney U-test was used to compare the differences between the SUVmax and PLR among the different clinical characteristics of patients with NPC and the 5-year progression-free survival (PFS) rate; according to the receiver operating characteristic (ROC) curve, the best cutoff values of the SUVmax and PLR were obtained and used to group patients. The Kaplan-Meier method and Log-rank test were used to conduct univariate analysis of 5-year PFS in patients with NPC, and Cox regression was used to conduct multivariate analysis; differences in the 5-year PFS of patients with different SUVmax values combined with the PLR were compared.

RESULTS: The SUVmax and PLR of patients with disease progression within 5 years were higher than those of patients without disease progression (p = 0.006 and p = 0.026). SUVmax = 9.7 and PLR = 132.98 had the best prognostic diagnostic efficiency for patients. Cox multivariate analysis showed that the SUVmax and PLR are independent factors affecting the prognosis of NPC. The 5-year PFS of patients with SUVmax <9.7 was significantly higher than that of patients with SUVmax ≥9.7 in the high PLR group (PLR ≥132.98) and in the low PLR group (PLR <132.98) (59.3% vs 29.4%, p = 0.033 and 90.9% vs 42.9%, p = 0.006, respectively). For patients with SUVmax <9.7, the 5-year PFS of the high PLR group was significantly lower than the low PLR group (59.3% vs 90.9%, p = 0.016); for patients with SUVmax ≥9.7, there was no significant difference in 5-year PFS between the high PLR group and the low PLR group (29.4% vs 42.9%, p = 0.406).

CONCLUSIONS: Both the SUVmax of the primary tumor and the PLR before treatment have an important influence on the prognosis of NPC. Combining the SUVmax and the PLR can more accurately predict the prognosis of patients with NPC.

ADVANCES IN KNOWLEDGE: In this study, we evaluated the prognostic value of combining pretreatment tumor 18F-FDG uptake on PET/CT imaging and PLR in NPC patients. We found that both SUVmax and PLR are independent factors for the PFS of NPC patients, and a low SUVmax (SUVmax <9.7) combined with a low PLR (PLR <132.98) revealed significant PFS benefit.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Xian, Feng, Wang, et al. Usefulness of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography combined with the platelet-lymphocyte ratio in predicting the prognosis of nasopharyngeal carcinoma. Br J Radiol. 2021. PMID: 34813375. doi:10.1259/bjr.20210279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。